IP Library Granted Patent US 8,148,332
Granted Patent B2
US 8,148,332 · App. 13/191,923 · Granted Apr 3, 2012

Method for treating a rheumatic disease using a soluble TLA4 molecule

Assignee: Bristol-Myers Squibb Company
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,148,332
App. No.
13/191,923
Granted
Apr 3, 2012
Kind
B2
Abstract

The present invention relates to compositions and methods for treating rheumatic diseases, such as psoriasis arthropathica, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.

Claims (12)

1. A method of treating rheumatic diseases in a subject comprising administering to the subject a CTLA4 molecule, wherein the CTLA4 molecule comprises:

(a) an amino acid sequence beginning with methionine at position +1 and ending with aspartic acid at position 124 of SEQ ID NO:17, or

(b) an amino acid sequence beginning with alanine at position −1 and ending with aspartic acid at position 124 of SEQ ID NO:17 and wherein said rheumatic disease is psoriasis arthropathica.

2. The method of claim 1 , wherein the extracellular domain of the CTLA4 molecule is joined to a non-CTLA4 molecule.

3. The method of claims 2 , wherein the non-CTLA4 molecule comprises an amino acid sequence which alters the solubility or affinity of the CTLA4 molecule.

4. The method of claim 3 , wherein the amino acid sequence which alters the solubility or affinity comprises an immunoglobulin moiety.

5. The method of claim 4 , wherein the immunoglobulin moiety is an immunoglobulin constant region or portion thereof.

6. The method of claim 5 , wherein the immunoglobulin constant region or portion thereof is mutated to reduce effector function.

7. The method of claim 6 , wherein the immunoglobulin constant region or portion thereof comprises a hinge, CH2 and CH3 regions of a human or monkey immunoglobulin molecule.

8. A method of treating rheumatic diseases in a subject comprising administering to the subject a CTLA4 molecule, wherein the CTLA4 molecule comprises:

(a) an amino acid sequence beginning with methionine at position +1 and ending with lysine at position 357 of SEQ ID NO:19, or

(b) an amino acid sequence beginning with alanine at position −1 and ending with lysine at position 357 of SEQ ID NO:19 and wherein said rheumatic disease is psoriasis arthropathica.

Continuity (6)
Continuation 10419008 · Apr 18, 2003
Continuation In Part 09898195 · Jul 2, 2001
Provisional Application 60215913 · Jul 3, 2000
Provisional Application 60373852 · Apr 19, 2002
Provisional Application 60407246 · Aug 30, 2002
Related Publication 20110311529A1 · Dec 22, 2011